Panacea Pharmaceuticals, Inc. President/CEO Presents Update on Alzheimer's Disease Drug Development Program During Interview on CEOcast.com

ROCKVILLE, Md.--(BW HealthWire)--December 20, 2000--Panacea Pharmaceuticals, Inc. announced that its President and CEO, Hossein A. Ghanbari, Ph.D., was interviewed today by CEOcast, Inc., the premier source of original and syndicated streaming broadcast interviews of CEOs at public and private news-making companies.

During the interview, Dr. Ghanbari gave an overview of the Company's drug development programs for Alzheimer's disease, brain cancer, and Parkinson's disease.

In discussing the Alzheimer's disease drug development program, Dr. Ghanbari explained the Company's approach of creating an integrated, multi-technology approach that would converge to produce highly relevant drug candidates aimed at protecting brain cells from degenerating. Dr. Ghanbari also discussed the Company's partnering strategy for this program.

The interview can be accessed at www.CEOcast.com. A simple, free registration is required.

About CEOcast

CEOcast, Inc. is a leading on-line resource for professional investors seeking information on emerging growth companies. It interviews CEOs in connection with breaking news stories and earnings announcements. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street's leading companies.

CEOcast's programming is distributed to millions of on-line investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts, and traders at over 3,300 North American institutions. Content is also disseminated to nearly 7,000 investment research professionals representing more than 425 institutions.

About Panacea Pharmaceuticals

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system and cancer such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease.

Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents.